Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
For the past decade we have been struggling to create and re-create anti-HIV regimens that contain three active drugs from the same three basic drug classes: nucleoside reverse transcriptase inhibitors, nonnukes, and protease inhibitors--with a little help from fusion inhibitor T-20 (Fuzeon) once it was introduced in 2003. Over time, regimens have failed in some experienced patients, and the number of patients without any viable treatment options has increased. In addition, in parts of the country up to 15% of newly infected patients have a virus already resistant to at least one drug class. But as we begin 2008 I feel like we are entering what future historians might call the golden age of anti-HIV medications. This era actually started two years ago with the second-generation protease inhibitors, darunavir (Prezista) and tipranavir (Aptivus). Then in August a new class of drugs called coreceptor blockers arrived with the Food and Drug Administration's approval of maraviroc (Selzentry). Barely two months later, another new class called integrase inhibitors debuted with raltegravir (Isentress). If all goes according to schedule, a second-generation nonnuke will be approved early this year. And if we are lucky, drugs farther up the pipeline--maturation inhibitors, monoclonal CD4 antibodies, and second-generation nucleosides--will prove successful as well. This optimism is reflected in changes made to the most recent treatment guidelines of both the U.S. Department of Health and Human Services and the International AIDS Society-USA. Prior guidelines admitted that the goal of maximal suppression of viral loads to below 50 might not be possible in patients with broad treatment experience. But these current guidelines have a goal of viral loads below 50 in all patients, regardless of past medication exposure. Based on studies of maraviroc and raltegravir, these goals seem possible. In separate studies patients who were already three-class resistant were randomized to the study drug or placebo plus an optimized background therapy. At 24 weeks the arm with the study drug had about twice the percentage of patients with undetectable viral loads compared to placebo. And if the study drug was combined with an optimized background therapy containing two or more active drugs, 60% to 80% of patients achieved undetectable status. In other words, having several new classes of drugs to which there is no resistance should get about 70% of our currently unsalvageable patients to undetectable viral levels. However, amid all this optimism, we need to remember that we must not squander this bounty of new drugs. Resistance will surely arise if we fail to patiently wait to create a regimen with three active components for each patient. Let's celebrate where we are but not forget where we have been. Bowers is an HIV specialist and board-certified physician in family practice, and he is a senior partner with Pacific Oaks Medical Group, one of the largest U.S. practices devoted to HIV care, in Beverly Hills, Calif.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
'Drag Race' star Q shares she's living with HIV
March 18 2024 3:08 PM
Plus: Featured Video
Latest Stories
La ciencia detrás de U=U ha estado liberando a las personas con VIH durante años
August 23 2024 2:48 PM
Tratamiento y prevención del VIH por inyección: Todo lo que necesita saber
August 23 2024 2:41 PM
Sr. Gay World quiere asegurarse de que estés bien
August 23 2024 2:30 PM
Eureka is taking a break from competing on 'Drag Race' following 'CVTW' elimination
August 20 2024 12:21 PM
With a new case in Sweden, what is the new mpox outbreak and should you be concerned?
August 15 2024 4:48 PM
The freedom of disclosure: David Anzuelo's journey through HIV, art, and advocacy
August 02 2024 12:21 PM
From ‘The Real World’ to real life: How Danny Roberts thrives with HIV
July 31 2024 5:23 PM
The July/Aug 'Treatment Guide' issue of Plus is here!
June 26 2024 3:49 PM
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM